Pulmonary hypertension (PH) affects approximately 10% of adult patients with sickle cell disease (SCD), particularly those with the homozygous genotype. An increase in pulmonary artery systolic pressure, estimated noninvasively by echocardiography, helps identify SCD patients at risk for PH but definitive diagnosis requires right heart catheterization. About half of SCD-related PH patients have pre-capillary PH with potential etiologies of 1) an NO deficiency state and vasculopathy consequent to intravascular hemolysis, 2) chronic pulmonary thromboembolism, or 3) upregulated hypoxic responses secondary to anemia, low O2 saturation and microvascular obstruction. The remainder have post-capillary PH secondary to left ventricular dysfunction. Though the pulmonary artery pressure in SCD patients with PH is only moderately elevated, they have a markedly higher risk of death than patients without PH.
Sickle cell disease (SCD) is due to homozygosity for a Glu6Val mutation in HBB (sickle cell anemia; hemoglobin SS) or to compound heterozygous forms like hemoglobin SC disease and hemoglobin S-β thalassemia. This mutation results in the synthesis of a structurally abnormal hemoglobin (hemoglobin S). Hemoglobin S polymerization is ultimately responsible for adverse effects of hemolysis, vaso-occlusion, chronic inflammation, anemia and up-regulation of hypoxic responses.
1,2 Pulmonary hypertension (PH) is relatively common in SCD and needs to be considered both in the broader picture of PH in patients without SCD and also with the view that SCD pathophysiology impacts the pathogenesis, classification, and prognosis of this disorder.
Pulmonary hypertension, its classification and pathology. The World Symposium on
Pulmonary Hypertension defines PH as mean pulmonary artery pressure ≥ 25 mm Hg at rest as determined by right heart catherization. 3 The upper level of normal for mean pulmonary artery pressure is 20 mm Hg, and the clinical significance of patients with mean pulmonary artery pressure between 21 and 24 mm Hg is under discussion. Some authorities consider this range to specify borderline PH, and this range may identify subjects with reduced exercise capacity and poor outcomes. 4 Clinically, PH is divided into five broad categories as shown in Table 1 . 5 In its guidelines 7 Expansion of cells surrounding the media-fibroblasts, progenitor cells, macrophages and other immune cells -leads to thickening of the adventitia, a layer that serves as a resource for the repair of vessel injury. 8 Changes typical of pulmonary arterial hypertension may be found to varying degrees in the other forms of PH as well. In addition, Group 2 PH due to left heart disease features enlarged pulmonary veins and capillaries. In Group 4 chronic thromboembolic PH (CTEPH), 5 organized thrombi replace the intima of proximal or distal elastic pulmonary arteries and attach to the medial layer, causing variable degrees of stenosis or complete occlusion of the lumen. Changes similar to pulmonary arterial hypertension can develop in the non-occluded areas, and collateral vessels from the systemic circulation may grow to re-perfuse areas of complete obstruction.
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Hemodynamically, PH is subdivided as pre-capillary PH if the pulmonary capillary wedge pressure (PCWP) or left ventricular end-diastolic pressure (LVEDP) at right heart catheterization is ≤ 15 mm Hg and as post-capillary PH if the PCWP/LVEDP is >15 mm Hg (Figure 1b) . 5 For practical purposes, the hemodynamic grouping of post-capillary PH and the clinical grouping of Group 2 PH refer to the same entity.
Echocardiography to screen for pulmonary hypertension
Echocardiography to screen for PH in patients without SCD. In general, the tricuspid regurgitation velocity (TRV) measured during echocardiography in combination with estimated right atrial pressure is considered to be a valid estimate of systolic pulmonary artery pressure. 9, 10 The normal TRV is considered to be <2.5 m/sec, but elevation of TRV and estimated systolic pulmonary artery pressure does not reliably identify subjects with PH defined as mean pulmonary arterial pressure ≥ 25 mm Hg. Rather, an elevated TRV can help identify
For personal use only. on November 1, 2017. by guest www.bloodjournal.org From subjects who should be examined definitively with right heart catheterization. PH is considered to be unlikely if the TRV is ≤ 2.8 m/sec and there are no other echocardiographic changes suggestive of PH such as enlargement of right-sided chambers and right ventricular systolic dysfunction. The diagnosis is considered to be possible if the TRV is 2.9-3-4 m/sec and to be likely if it is >3.4 m/sec. 5 Echocardiography to screen for PH in SCD. Several studies have documented a positive correlation of TRV and echocardiography-estimated systolic pulmonary artery pressure with systolic pulmonary pressure measured at right heart catheterization in patients with SCD. In these studies, the correlation coefficient r has ranged from 0.645 to 0.77, P <0.001. [11] [12] [13] Several studies, some overlapping, have also addressed the positive predictive value of specific TRV values for right heart catheterization-documented PH, and these are summarized in Table 2 .
Based on these studies, more than half of SCD patients with TRV ≥ 2.9 m/sec have PH on right heart catheterization while less than 15% of those with TRV 2.5 to 2.8 m/sec have PH.
However, performing right heart catheterizations only in SCD patients with TRV of 2.9 m/sec or higher leads to a failure to diagnose PH in about 4 of 10 patients with the condition. 11 The accuracy of non-invasive diagnosis of PH in SCD could be improved by a multi-modality approach: the combination of TRV 2.5-2.8 m/s, NT-proBNP >164.5 pg/ml and six-minute walk distance less than 333 m had a positive predictive value of 62% with a false-negative rate of 7%. 11 Therefore SCD patients with TRV of 2.5-2.8 m/sec should be considered for right heart catheterization if there are other findings that suggest PH such as dyspnea on exertion, increased brain natriuretic peptide, right ventricular hypertrophy by echocardiography and/or limited exercise capability.
Prevalence and mortality of pulmonary hypertension in patients with SCD. Three studies conducted based on screening for PH with echocardiography and confirming the diagnosis with right heart catheterization have indicated a minimum prevalence of PH in adults with SCD of For personal use only. on November 1, 2017. by guest www.bloodjournal.org From 6.0-10.4% (Table 3 ). An emphasis should be placed on the fact that these are minimum estimates. In the study from France, which reports the lowest PH prevalence, more than 10% of the patients from the background population were excluded from the study because of kidney disease (creatinine clearance <30 ml/minute) and other severe manifestations; 11 a substantial proportion of these subjects would be expected to have PH on right heart catheterization. In all three studies, not all of the subjects who were eligible for a right heart catheterization underwent the procedure (Table 3 ) and no doubt some cases of PH were missed because of this.
These and other studies have documented a marked increase in mortality rate in SCD patients with PH. 11, 13, 14 In the report from France, 3 (12.5%) of 24 patients with PH died over three years compared to 3 (0.8%) of 379 without the diagnosis. 11 In the report from Brazil, mortality over up to three years of follow-up was 37.5% among eight patients with PH compared to 5.6% among 72 without (P = 0.0005). 13 In the report from the United States, the six-year mortality rate was 37% among 55 patients with PH compared to 17% among 447 without (P = 0.006). 14 In an earlier report from the United States of patients undergoing right heart catheterization, 11 (55.0%) of 20 patients with PH died over up to nine years of follow-up compared to 3 (21.4%) of 14 without PH.
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Two of the three studies reporting prevalence of right heart catheterization-documented PH in SCD included only patients with severe sickling genotypes-hemoglobin SS and hemoglobin Sβ 0 -thalassemia. 11, 13 The third study 14 did include 92 patients (17.3%) with the milder hemoglbin SC genotype; 14 of these subjects underwent cardiac catheterization and 10 had PH. The low number of hemoglobin SC patients with catheterization-proven PH does not allow reliable prognosis estimates. However, a study using echocardiography to estimate elevated systolic pulmonary artery pressure in the various sickle genotypes showed that even though the frequency of elevated systolic pulmonary artery pressure was relatively low in hemoglobin SC disease, the risk of death in hemoglobin SC patients who had this abnormality was of the same magnitude as in hemoglobin SS patients.
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For personal use only. on November 1, 2017. by guest www.bloodjournal.org From Pathways of pre-capillary pulmonary hypertension in SCD. Slightly more than half of the reported cases of right heart catheterization-documented PH in SCD have pre-capillary PH ( further down-regulated expression was associated with right heart catheterization-documented pre-capillary PH in SCD. Abnormal proliferation of pulmonary vascular smooth muscle cells and resistance to apoptosis is a prominent feature of pulmonary arterial hypertension. 69 Expression of MAPK8 was down regulated in SCD and CP where the hypoxic response is up regulated, and the A allele of rs10857560 was associated with a further decrease in expression in SCD.
Homozygosity for the A allele was present in all 14 of the patients with pre-capillary PH that we examined, suggesting that the dosage effect of the A allele on MAPK8 gene expression might contribute to the pathogenic mechanism of pre-capillary PH in SCD. found not to have PH at right heart catheterization have similar survival to SCD patients without elevated TRV, 11, 13, 14 suggesting that the elevated mortality with high TRV is largely driven by the subset that does have PH.
A remarkable clinical feature of sickle-related PH is its high mortality despite relatively low mean pulmonary artery pressures. In contrast to other patients with pulmonary arterial hypertension (e.g. idiopathic, scleroderma-associated) where morbidity and mortality are
For personal use only. on November 1, 2017. by guest www.bloodjournal.org1 3 typically associated with mean pulmonary arterial pressures in the range of 50-60 mm Hg, in patients with SCD these phenomena are observed with mean pulmonary pressures in the range of 30-40 mm Hg, with mild elevations in pulmonary vascular resistance. 15, 19 In non-SCD patients with pulmonary arterial hypertension, the cardiac output is inversely related to mortality. 79 In SCD patients with or without PH, the cardiac output is considerably above the normal range for non-anemic individuals. From this perspective SCD PH patients might be expected to have a longer survival than pulmonary arterial hypertension patients without SCD, but this is not the case. It appears that in patients with anemia at the limits of cardiac output compensation, any degree of PH is poorly tolerated and results in significant morbidity and mortality. In addition,
complications that occur frequently in SCD, such as pain crises 80 and especially acute chest syndrome, 81 also acutely raise pulmonary pressures so that SCD patients with PH develop "acute on chronic" PH, making them less likely to survive these sickle-related complications. Table 5 .
For personal use only. on November 1, 2017. by guest www.bloodjournal.org From Future directions. Even minor degrees of anemia adversely affect survival in non-SCD pulmonary arterial hypertension patients.
83 Anemia was associated with higher mortality even though it increased cardiac output, a hemodynamic feature that predicts longer survival. It seems possible that the anemia of SCD patients could contribute to high mortality of SCD patients with PH although, as discussed above, the degree of elevation in mean pulmonary artery pressure is modest. 19 Case reports suggest that exchange blood transfusion, an intervention that improves anemia, is beneficial to SCD patients with PH. 84 Randomized, controlled trials of exchange transfusions in SCD patients with severe PH are needed to address their high mortality. Though such trials are still lacking, it seems probable that in the United States the median survival of adult SCD patients with PH has improved in the past decade in association with echocardiographic screening and better care of patients with this complication. Currently the median survival of SCD PH patients is more than six years, 14 or more than three times longer than that reported for a corresponding group of SCD PH patients studied over a decade ago of 2.1 y. 15 That the longer survival is not due to more severe patients being studied in the 2003 report is supported by the similarity in their pulmonary hemodynamics (mean pulmonary artery pressure of ~ 36 mm Hg in both series). Nor is it likely that the longer SCD PH patient survival is due merely to advances in general SCD medical care: for patients whose right heart catheterization results did not show PH, the survival was similar in both studies. It seems possible that routine ECHO screening of SCD adults over the last decade has identified a group of patients who have a higher risk of death and whose referral to SCD PH specialized centers has allowed interventions such as intensification of SCD-specific treatment and/or, in selected cases, pulmonary arterial hypertension-specific treatment that may have lowered their mortality. This encouraging trend should serve as a stimulus to conduct more controlled trials for reducing the mortality of PH in SCD, such as transfusion therapy and new pharmacological agents. Table 5 . Suggested approach to screening, diagnosis and management of PH in SCD 1. Screening for PH by echocardiography
• Perform echocardiography every 1 to 3 years, OR • Perform echocardiography based on one or more findings consistent with increased risk: -Dyspnea on exertion -Limited exercise capability as determined by the six minute walk test (<350 m) -History of thromboembolism -Pulse oximetry <96% at rest -Previous echocardiogram with TRV of 2.5 m/sec or greater -Physical findings of right sided heart failure: lower extremity edema, hepatomegaly or jugular venous distension -Elevated serum N-terminal proBNP concentration -Elevated serum creatinine concentration (>1.0 mg/dL for severe sickling phenotype and >1.4 mg/dL for mild sickling phenotype) -LDH >475 U/L or reticulocyte count >300,000 -Serum ferritin >1000 ng/ml 2. Actions to be taken based on the results of echocardiography
• TRV <2.5 m/sec-Ensure that patient is being managed according to NHLBI guidelines.
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• TRV 2.5-2.9 m/sec, right ventricle normal by echocardiography, no findings suggestive of PH-Ensure patient being managed according to NHLBI guidelines 82 and repeat echocardiogram yearly.
• TRV 2.5-2.9 m/sec, right ventricular hypertrophy by echocardiography and/or other findings consistent with increased PH risk-Ensure patient being managed according to NHLBI guidelines; 82 refer to PH expert for right heart catheterization.
• TRV of 3.0 m/sec or greater-Ensure patient is being managed according to NHLBI guidelines 82 and refer to expert in PH for right heart catheterization.
Actions to be taken based on the results of right heart catheterization
• mPAP <25 mm Hg: PH not present-Ensure patient is being managed according to NHLBI guidelines 82 and repeat echocardiogram yearly • mPAP 25 mm Hg or greater and PCWP ≤ 15 mm Hg: pre-capillary pulmonary PH -Perform ventilation/perfusion scan of lung and consider long-term anticoagulation if segmental defect found. -Refer for overnight polysomnography to evaluate for sleep disordered breathing including obstructive sleep apnea; provide appropriate intervention if present. -Chronic low flow oxygen by nasal cannula if pulse ox <90% -Refer to expert in PH for follow-up and consideration whether therapy with endothelin receptor blocker or prostacyclin agent should be attempted.* -Consider initiating therapy with hydroxyurea if patient is not receiving this medication or with exchange blood transfusion program if patient does not tolerate or respond to hydroxyurea. -Consider allogeneic hematopoietic stem cell transplantation with low-intensity conditioning regimen if patient has HLA-matched sibling.** • mPAP 25 mm Hg or greater and PCWP >15 mm Hg: post-capillary pulmonary PH -Refer to cardiologist to evaluate for left ventricular systolic or diastolic dysfunction; manage according to established guidelines for left ventricular failure.
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-Consider initiating therapy with hydroxyurea if patient not receiving this medication or with exchange blood transfusion program if patient does not tolerate or respond to hydroxyurea.
-Consider allogeneic hematopoietic stem cell transplantation with low-intensity conditioning regimen if patient has HLA-matched sibling. *There have been reports that some treatments effective for pulmonary arterial hypertension in patients without SCD also improve SCD-related PH with hemodynamic parameters consistent with pulmonary arterial hypertension. [86] [87] [88] **Successful lung transplantation, with intensive pre-and post-operative transfusion support, has been reported in a Hb SS patient with refractory PH. The patient was maintained with a hemoglobin S percent <10% after transplant through exchange blood transfusion.
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